A recent study published in Nature and reported by multiple scientific sources has identified lithium depletion in the brain as a potential early trigger of Alzheimer's disease. Research conducted on mouse models demonstrated that lithium deficiency impairs the clearance of amyloid plaques, a hallmark of Alzheimer's pathology, and leads to worsened memory performance. Mice deprived of lithium showed nearly 2.5 times more amyloid plaques compared to those on a standard diet. Importantly, replenishing lithium levels in the brain, specifically through low doses of lithium orotate, was able to reverse memory loss and other disease features in these animal models. The study highlights lithium as the only metal significantly decreased in the brains of individuals with mild cognitive impairment, a precursor to Alzheimer's disease, with further reduction observed in Alzheimer's patients due to amyloid sequestration. This research suggests that restoring natural lithium levels in the brain could offer a novel and safe therapeutic approach for both prevention and treatment of Alzheimer's disease in humans. Additional research from MIT points to new drug targets related to DNA repair and RNA modification as complementary avenues in Alzheimer's treatment development.